Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings: Perioperative Risks.

Nishizaki D, Eskander RN

Open source

DOI
10.1016/j.hoc.2026.05.017
Published
2026 Oct
Container
Hematology/oncology clinics of North America
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.hoc.2026.05.017,
  title = {Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings: Perioperative Risks.},
  author = {Nishizaki D and Eskander RN},
  year = {2026},
  journal = {Hematology/oncology clinics of North America},
  doi = {10.1016/j.hoc.2026.05.017},
  url = {https://doi.org/10.1016/j.hoc.2026.05.017}
}

RIS

TY  - JOUR
TI  - Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings: Perioperative Risks.
AU  - Nishizaki D
AU  - Eskander RN
PY  - 2026
JO  - Hematology/oncology clinics of North America
DO  - 10.1016/j.hoc.2026.05.017
UR  - https://doi.org/10.1016/j.hoc.2026.05.017
ER  - 

APA

D, N., & RN, E. (2026). Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings: Perioperative Risks.. Hematology/oncology clinics of North America. https://doi.org/10.1016/j.hoc.2026.05.017

Source records